Terms: = Breast cancer AND FES, FPS, 2242, ENSG00000182511, P07332 AND Staging
26 results:
1. Women's Health Update: Growing Role of PET for Patients with breast cancer.
Ulaner GA; Vaz SC
Semin Nucl Med; 2024 Mar; 54(2):247-255. PubMed ID: 38365547
[TBL] [Abstract] [Full Text] [Related]
2. Quarter-Century Transformation of Oncology: Positron Emission Tomography for Patients with breast cancer.
Ulaner GA; Vaz SC; Groheux D
PET Clin; 2024 Apr; 19(2):147-162. PubMed ID: 38177052
[TBL] [Abstract] [Full Text] [Related]
3. Summary: SNMMI Procedure Standard/EANM Practice Guideline for Estrogen Receptor Imaging of Patients with breast cancer Using 16α-[
Mankoff D; Balogová S; Dunnwald L; Dehdashti F; DeVries E; Evangelista L; Van Kruchten M; Vaz SC; Fowler A; Linden H; Ulaner GA
J Nucl Med; 2024 Feb; 65(2):221-223. PubMed ID: 38071554
[TBL] [Abstract] [Full Text] [Related]
4. Clinical Applications of Dedicated breast Positron Emission Tomography.
Fowler AM; Miyake KK; Nakamoto Y
PET Clin; 2024 Jan; 19(1):105-117. PubMed ID: 37805387
[TBL] [Abstract] [Full Text] [Related]
5. Molecular Imaging for Estrogen Receptor-Positive breast cancer: Clinical Applications of Whole Body and Dedicated breast Positron Emission Tomography.
Goodman K; Abel MK; Lawhn-Heath C; Molina-Vega J; Jones EF; Mukhtar RA
Surg Oncol Clin N Am; 2022 Oct; 31(4):569-579. PubMed ID: 36243494
[No Abstract] [Full Text] [Related]
6. To Identify Small Bowel Metastasis From Lobular breast cancer on 18 F-Fluoroestradiol PET/CT : Necessary to Adjust the Background Uptake Level.
Lu Y
Clin Nucl Med; 2023 Feb; 48(2):192-193. PubMed ID: 36083216
[TBL] [Abstract] [Full Text] [Related]
7. Molecular Imaging Assessment of Hormonally Sensitive breast cancer: An Appraisal of 2-[18F]-Fluoro-2-Deoxy-Glucose and Newer Non-2-[18F]-Fluoro-2-Deoxy-Glucose PET Tracers.
Yadav D; Kumar R; Phulia A; Basu S; Alavi A
PET Clin; 2022 Jul; 17(3):399-413. PubMed ID: 35717099
[TBL] [Abstract] [Full Text] [Related]
8. PET Imaging of Estrogen Receptors for Gynecological Tumors.
Tsujikawa T; Makino A; Mori T; Tsuyoshi H; Kiyono Y; Yoshida Y; Okazawa H
Clin Nucl Med; 2022 Jul; 47(7):e481-e488. PubMed ID: 35675139
[TBL] [Abstract] [Full Text] [Related]
9. 18F-fes PET/CT Improves the Detection of Intraorbital Metastases in Estrogen-Receptor-Positive breast cancer: Two Representative Cases and Review of the Literature.
Bodapati S; Abraham P; Chen A; Guilbault D; McDonald M; Matro J; Shatsky R; Obrzut S
Tomography; 2022 Apr; 8(2):1060-1065. PubMed ID: 35448720
[TBL] [Abstract] [Full Text] [Related]
10. 16α-18F-fluoro-17β-Fluoroestradiol (fes): Clinical Applications for Patients With breast cancer.
Ulaner GA
Semin Nucl Med; 2022 Sep; 52(5):574-583. PubMed ID: 35379454
[TBL] [Abstract] [Full Text] [Related]
11. Whole-Body Characterization of Estrogen Receptor Status in Metastatic breast cancer with 16α-18F-Fluoro-17β-Estradiol Positron Emission Tomography: Meta-Analysis and Recommendations for Integration into Clinical Applications.
Kurland BF; Wiggins JR; Coche A; Fontan C; Bouvet Y; Webner P; Divgi C; Linden HM
Oncologist; 2020 Oct; 25(10):835-844. PubMed ID: 32374053
[TBL] [Abstract] [Full Text] [Related]
12.
Liu C; Gong C; Liu S; Zhang Y; Zhang Y; Xu X; Yuan H; Wang B; Yang Z
Oncologist; 2019 Dec; 24(12):e1277-e1285. PubMed ID: 31337657
[TBL] [Abstract] [Full Text] [Related]
13. Diagnostic accuracy and safety of 16α-[
Chae SY; Ahn SH; Kim SB; Han S; Lee SH; Oh SJ; Lee SJ; Kim HJ; Ko BS; Lee JW; Son BH; Kim J; Ahn JH; Jung KH; Kim JE; Kim SY; Choi WJ; Shin HJ; Gong G; Lee HS; Lee JB; Moon DH
Lancet Oncol; 2019 Apr; 20(4):546-555. PubMed ID: 30846327
[TBL] [Abstract] [Full Text] [Related]
14. Simultaneous breast cancer and DLBCL lymphoma - role of PET/CT examination with 18F-FDG and 18F-fes.
Hołody Ł; Kunikowska J; Braziewicz J
Nucl Med Rev Cent East Eur; 2018; 21(2):113-114. PubMed ID: 29956818
[TBL] [Abstract] [Full Text] [Related]
15. 18F-Fluoroestradiol PET/CT Correctly Diagnosed 18F-FDG-Avid Inflammatory Lymph Nodes in a Patient With Estrogen Receptor-Positive breast cancer.
Yamane T; Ueda S; Seto A; Kuji I
Clin Nucl Med; 2018 May; 43(5):379-380. PubMed ID: 29485433
[TBL] [Abstract] [Full Text] [Related]
16. 18F-fes PET Has Added Value in staging and Therapy Decision Making in Patients With Disseminated Lobular breast cancer.
Venema C; de Vries E; Glaudemans A; Poppema B; Hospers G; Schröder C
Clin Nucl Med; 2017 Aug; 42(8):612-614. PubMed ID: 28604479
[TBL] [Abstract] [Full Text] [Related]
17. Translation of New Molecular Imaging Approaches to the Clinical Setting: Bridging the Gap to Implementation.
van Es SC; Venema CM; Glaudemans AW; Lub-de Hooge MN; Elias SG; Boellaard R; Hospers GA; Schröder CP; de Vries EG
J Nucl Med; 2016 Feb; 57 Suppl 1():96S-104S. PubMed ID: 26834109
[TBL] [Abstract] [Full Text] [Related]
18. The value of PET/CT with fes or FDG tracers in metastatic breast cancer: a computer simulation study in ER-positive patients.
Koleva-Kolarova RG; Greuter MJ; van Kruchten M; Vermeulen KM; Feenstra T; Buskens E; Glaudemans AW; de Vries EF; de Vries EG; Hospers GA; de Bock GH
Br J Cancer; 2015 May; 112(10):1617-25. PubMed ID: 25880006
[TBL] [Abstract] [Full Text] [Related]
19. PET Imaging of breast cancer: Role in Patient Management.
Lebron L; Greenspan D; Pandit-Taskar N
PET Clin; 2015 Apr; 10(2):159-95. PubMed ID: 25829085
[TBL] [Abstract] [Full Text] [Related]
20. Current applications of PET imaging of sex hormone receptors with a fluorinated analogue of estradiol or of testosterone.
Talbot JN; Gligorov J; Nataf V; Montravers F; Huchet V; Michaud L; Ohnona J; Balogova S; Cussenot O; Daraï E; Lotz JP; Kerrou K
Q J Nucl Med Mol Imaging; 2015 Mar; 59(1):4-17. PubMed ID: 25693420
[TBL] [Abstract] [Full Text] [Related]
[Next]
